Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

2018 Saw Record Launches, But No Big Splash

Executive Summary

The number of US drug approvals in 2018 was striking, but most of the novel products launched last year are for rare diseases or niche cancers, meaning commercial success may be in the eye of the beholder.

Advertisement

Related Content

Orphan Drugs Compose Majority Of Novel US Approvals For First Time Ever In 2018
FDA Nod For Loxo/Bayer Tissue Agnostic Drug Marks Paradigm Shift In Cancer
Teva Stands By Migraine Strategy After Ajovy Misses Boat On Express Scripts Deal
Keeping Track: Three Oncologics, A New Migraine Preventive, And First LPAD Antibiotic Clear US FDA
Alnylam Offers Flexible Value-Based Deals For Breakthrough RNAi Drug Onpattro
BioMarin Gets Second PKU Approval, Anticipates Slow Ramp-Up For Palynziq
Ultragenyx Gets Second Drug Approval; Crysvita With Kyowa Hakko Kirin
Vertex Eyes Triple Glory After Hat Trick of CF Approvals
Roche's Ocrevus: A Rare First-Year Blockbuster
A Year To Remember For US Drug Launches

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC125022

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel